10, 1997; U. S. Serial No. 60/071,141 filed January 12, 1998 and; U. S. Serial No. 60/074,675, filed February 13, 1998. This application further claims the benefit of the filing dates of U.S. Serial No. 60/113,230 filed December 21, 1998, U.S. Serial No. 60/120,536 filed February 17, 1999, and U.S. Serial No. 60/124,658 filed March 16, 1999. The contents of all of the foregoing applications are incorporated by reference into the present application. --

Please replace the paragraph beginning at page 6, line 13 with the following rewritten paragraph:

-- **FIG. 1A.** Nucleotide sequence (SEQ ID NO:1, ATCC Designation 209612) of a cDNA encoding human PSCA.

FIG. 1B. Translated amino acid sequence (SEQ ID NO:2) of human PSCA. -- .

Please replace the paragraph beginning at page 6, line 16 with the following rewritten paragraph:

-- **FIG. 2.** Nucleotide sequence (SEQ ID NO:3), of a murine cDNA PSCA homologue and the translated amino acid sequence (SEQ ID NO:4) of murine PSCA. -- .

IN THE CLAIMS:

Please cancel claims 2-52 without prejudice to pursue the subject matter of these claims in a related application.

Please add new claims 53-69 as follows:

--53. (NEW) A Prostate Stem Cell Antigen (PSCA) protein fragment which induces an immune response in a subject, wherein the fragment comprises a portion of the PSCA protein. --

-- 54. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 1 through 123 as described in SEQ ID NO:2. --

-- 55. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 2 through 50 as described in SEQ ID NO:2. --

-- 56. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 85 through 123 as described in SEQ ID NO:2. --

-- 57. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 46 through 109 as described in SEQ ID NO:2. --

-- 58. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 18 through 98 as described in SEQ ID NO:2. --

-- 59. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 22 through 99 as described in SEQ ID NO:2. --

-- 60. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 21 through 50 as described in SEQ ID NO:2. --

-- 61. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 46 through 85 as described in SEQ ID NO:2. --

-- 62. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 50 through 64 as described in SEQ ID NO:2. --

-- 63. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 67 through 81 as described in SEQ ID NO:2. --

-- 64. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 21 through 99 as described in SEQ ID NO:2. --

-- 65. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 71 through 82 as described in SEQ ID NO:2. --

-- 66. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 85 through 99 as described in SEQ ID NO:2. --

-- 67. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 18 through 50 as described in SEQ ID NO:2. --

-- 68. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 46 through 98 as described in SEQ ID NO:2. --

-- 69. (NEW) The PSCA protein fragment of claim 53, consisting of amino acid residues 85 through 98 as described in SEQ ID NO:2. --

REMARKS

By way of this Preliminary Amendment, applicants cancelled claims 2-52 and applicants add new claims 53-69. Accordingly, claims 1 and 53-69 are pending.

The amendment to the specification at the paragraph beginning at line 5, page 1, is merely to state the priority information and does not constitute new matter.